NGFRhi cells are associated with intrinsic cross-resistance to T effector cells recognizing melanoma tumor antigens unrelated to differentiation, as well as with resistance to other clinically relevant therapies, including combinatorial BRAF + MEK inhibition. This evidence concerns the gene MAP2K7 and neoplasm.